THE IMPACT OF METHADONE OR BUPRENORPHINE TREATMENT AND ONGOING INJECTION ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ADHERENCE: EVIDENCE FROM THE MANIF2000 COHORT STUDY

Documenti analoghi

• SELF REPORTED SIDE EFFECTSIN BUPRENORPHINE AND METHADONE PATIENTS RECEIVING ANTIRETROVIRAL THERAPY: RESULTS FROM THE MANIF 2000 COHORT STUDY
  di: CARRIERI, M.P
• ACCES TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) FOR INJECTING DRUG USERS IN THE WHO EUROPEAN REGION 2002-2004
  di: DONOGHOE, M.C
• Adherence to highly active antiretroviral therapy in Spain. A meta-analysis
  di: Ortego, C.
• WITHDRAWAL SYMPTOMS AS A PREDICTOR OF MORTALITY IN PATIENTS HIV-INFECTED THROUGH DRUG USE AND RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
  di: MICHEL, L.
• Ongoing impact of HIV infection on mortality among people who inject drugs despite free antiretroviral therapy
  di: Lappalainen, L.